1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Portugal Pharmaceuticals and Healthcare Report Q4 2016

Portugal Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 101 pages

Includes 3 FREE quarterly updates

BMI View:

Although we see limited chances for Portugal to improve its competitiveness in order to attract foreign investment in the near future, rising private consumption and fiscal policy will support pharmaceutical and healthcare market growth rates over a multi-quarter horizon. In addition, as the economy continues to recover, the expansion of healthcare coverage will support rising demand for medical treatment. That said, cost-control measures will translate to marginal pharmaceutical sales growth, weighing on the market potential appeal for drugmakers.

Headline Expenditure Projections


- Pharmaceuticals: EUR3.44bn (USD3.81bn) in 2015 to EUR3.45bn (USD3.70bn) in 2016; +0.3% in local currency and -3.2% in US dollar terms. Forecast broadly in line with the last quarter.

- Healthcare: EUR16.71bn (USD18.54bn) in 2015 to EUR16.98bn (USD18.17bn) in 2016; +1.6% in local currency and -2.0% in US dollar terms. Forecast broadly in line with the last quarter.

Table Of Contents

Portugal Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Portugal 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Portugal 2012-2020) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Portugal 2012-2020) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts 18
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Portugal 2012-2020) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Portugal 2012-2020) 25
Generic Drug Market Forecast 26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Portugal 2012-2020) 28
Table: Top Generic Drugs By Value, 2011 28
Table: Average Price Of Top Generic Drugs By Value, 2010-2011 29
OTC Medicines Market Forecast 30
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Portugal 2012-2020) 32
Table: OTC Sales Outside Pharmacies By Therapeutic Group, January-September 2012 33
Table: OTC Sales Outside Pharmacies By District, January-September 2012 33
Table: OTC Sales Outside Pharmacies By Sales Outlet, January-September 2012 34
Table: Portugal OTC Sales Outside Pharmacies By Active Ingredient, January-September 2012 34
Pharmaceutical Trade Forecast 35
Table: Pharmaceutical Trade Data And Forecasts (Portugal 2014-2020) 38
Table: Pharmaceutical Trade Data And Forecasts local currency (Portugal 2014-2020) 38
Industry Risk/Reward Index 39
Western Europe Risk/Reward Index 39
Portugal Risk/Reward Index 45
Rewards 45
Risks 46
Regulatory Review 47
Regulatory Regime 47
Intellectual Property Issues 53
Pricing Regime 54
Reimbursement Regime 57
Pharmacoeconomics 58
Market Overview 60
Healthcare Sector 61
Table: Healthcare Resources (Portugal 2010-2015) 65
Table: Healthcare Personnel (Portugal 2010-2015) 65
Table: Healthcare Activity (Portugal 2010-2015) 66
Clinical Trials 66
Epidemiology 68
Competitive Landscape 70
Research-Based Industry 70
Generic Drugmakers 71
Table: Table: Multinational Market Activity 72
Pharmaceutical Distribution 72
Pharmaceutical Retail Sector 73
Table: Number Of Pharmaceutical Companies, Wholesalers, Pharmacies, Pharmacy Extensions And Drug Stores In Portugal 76
Company Profile 77
Bial 77
Bluepharma 81
Hovione 84
Medinfar 88
Demographic Forecast 90
Table: Population Headline Indicators (Portugal 1990-2025) 91
Table: Key Population Ratios (Portugal 1990-2025) 91
Table: Urban/Rural Population and Life Expectancy (Portugal 1990-2025) 92
Table: Population By Age Group (Portugal 1990-2025) 92
Table: Population By Age Group % (Portugal 1990-2025) 93
Glossary 95
Methodology 97
Pharmaceutical Expenditure Forecast Model 97
Healthcare Expenditure Forecast Model 97
Notes On Methodology 98
Risk/Reward Index Methodology 99
Index Overview 100
Table: Pharmaceutical Risk/Reward Index Indicators 100
Indicator Weightings 101

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.